These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 27448775)

  • 21. Novel 2-phenylquinolin-7-yl-derived imidazo[1,5-a]pyrazines as potent insulin-like growth factor-I receptor (IGF-IR) inhibitors.
    Mulvihill MJ; Ji QS; Coate HR; Cooke A; Dong H; Feng L; Foreman K; Rosenfeld-Franklin M; Honda A; Mak G; Mulvihill KM; Nigro AI; O'Connor M; Pirrit C; Steinig AG; Siu K; Stolz KM; Sun Y; Tavares PA; Yao Y; Gibson NW
    Bioorg Med Chem; 2008 Feb; 16(3):1359-75. PubMed ID: 17983756
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of novel imidazo[1,2-a]pyrazin-8-amines as Brk/PTK6 inhibitors.
    Zeng H; Belanger DB; Curran PJ; Shipps GW; Miao H; Bracken JB; Arshad Siddiqui M; Malkowski M; Wang Y
    Bioorg Med Chem Lett; 2011 Oct; 21(19):5870-5. PubMed ID: 21855335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of 3H-imidazo[4,5-b]pyridines as potent c-Met kinase inhibitors: design, synthesis, and biological evaluation.
    Chen D; Wang Y; Ma Y; Xiong B; Ai J; Chen Y; Geng M; Shen J
    ChemMedChem; 2012 Jun; 7(6):1057-70. PubMed ID: 22581753
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery and SAR study of c-Met kinase inhibitors bearing an 3-amino-benzo[d]isoxazole or 3-aminoindazole scaffold.
    Jiang X; Liu H; Song Z; Peng X; Ji Y; Yao Q; Geng M; Ai J; Zhang A
    Bioorg Med Chem; 2015 Feb; 23(3):564-78. PubMed ID: 25537530
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of triazolo[4,5-b]pyrazine derivatives as hepatocyte growth factor receptor inhibitors through structure-activity relationships and molecular docking simulations.
    Dong M; Ren Y; Gao X
    Bioorg Med Chem Lett; 2015 Oct; 25(19):4118-26. PubMed ID: 26321362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and biological evaluation of 3-(imidazo[1,2-a]pyrazin-3-ylethynyl)-2-methylbenzamides as potent and selective pan-tropomyosin receptor kinase (TRK) inhibitors.
    Cui S; Wang Y; Wang Y; Tang X; Ren X; Zhang L; Xu Y; Zhang Z; Zhang ZM; Lu X; Ding K
    Eur J Med Chem; 2019 Oct; 179():470-482. PubMed ID: 31271959
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel 5-(benzyloxy)pyridin-2(1H)-one derivatives as potent c-Met inhibitors.
    Zhang D; Ai J; Liang Z; Zhu W; Peng X; Chen X; Ji Y; Jiang H; Luo C; Geng M; Liu H
    Bioorg Med Chem Lett; 2013 Apr; 23(8):2408-13. PubMed ID: 23474386
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Target identification, lead optimization and antitumor evaluation of some new 1,2,4-triazines as c-Met kinase inhibitors.
    El-Wakil MH; Ashour HM; Saudi MN; Hassan AM; Labouta IM
    Bioorg Chem; 2017 Aug; 73():154-169. PubMed ID: 28715754
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design and synthesis of new imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrazine derivatives with antiproliferative activity against melanoma cells.
    Garamvölgyi R; Dobos J; Sipos A; Boros S; Illyés E; Baska F; Kékesi L; Szabadkai I; Szántai-Kis C; Kéri G; Őrfi L
    Eur J Med Chem; 2016 Jan; 108():623-643. PubMed ID: 26724730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective synthesis of benzimidazoles-imidazo[1,2-a]pyrazine conjugates: A comparative study of mono-and bis-benzimidazoles for antitumor activity.
    Singh I; Luxami V; Paul K
    Eur J Med Chem; 2019 Oct; 180():546-561. PubMed ID: 31344614
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.
    Bouloc N; Large JM; Kosmopoulou M; Sun C; Faisal A; Matteucci M; Reynisson J; Brown N; Atrash B; Blagg J; McDonald E; Linardopoulos S; Bayliss R; Bavetsias V
    Bioorg Med Chem Lett; 2010 Oct; 20(20):5988-93. PubMed ID: 20833547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis and biological evaluation of imidazo[1,5-a]pyrazin-8(7H)-one derivatives as BRD9 inhibitors.
    Zheng P; Zhang J; Ma H; Yuan X; Chen P; Zhou J; Zhang H
    Bioorg Med Chem; 2019 Apr; 27(7):1391-1404. PubMed ID: 30824168
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
    Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
    Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Discovery and optimization of pyrrolo[1,2-a]pyrazinones leads to novel and selective inhibitors of PIM kinases.
    Casuscelli F; Ardini E; Avanzi N; Casale E; Cervi G; D'Anello M; Donati D; Faiardi D; Ferguson RD; Fogliatto G; Galvani A; Marsiglio A; Mirizzi DG; Montemartini M; Orrenius C; Papeo G; Piutti C; Salom B; Felder ER
    Bioorg Med Chem; 2013 Dec; 21(23):7364-80. PubMed ID: 24139169
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors.
    Wang X; Jiang N; Zhao S; Xi S; Wang J; Jing T; Zhang W; Guo M; Gong P; Zhai X
    Bioorg Med Chem; 2017 Feb; 25(3):886-896. PubMed ID: 28011202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and SAR exploration of a novel series of imidazo[4,5-b]pyrazin-2-ones as potent and selective mTOR kinase inhibitors.
    Mortensen DS; Perrin-Ninkovic SM; Harris R; Lee BG; Shevlin G; Hickman M; Khambatta G; Bisonette RR; Fultz KE; Sankar S
    Bioorg Med Chem Lett; 2011 Nov; 21(22):6793-9. PubMed ID: 21978683
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design, synthesis and biological evaluation of c-Met kinase inhibitors bearing 2-oxo-1,2-dihydroquinoline scaffold.
    Cui H; Peng X; Liu J; Ma C; Ji Y; Zhang W; Geng M; Li Y
    Bioorg Med Chem Lett; 2016 Sep; 26(18):4483-4486. PubMed ID: 27524312
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imidazopyridine hydrazone derivatives exert antiproliferative effect on lung and pancreatic cancer cells and potentially inhibit receptor tyrosine kinases including c-Met.
    Damghani T; Moosavi F; Khoshneviszadeh M; Mortazavi M; Pirhadi S; Kayani Z; Saso L; Edraki N; Firuzi O
    Sci Rep; 2021 Feb; 11(1):3644. PubMed ID: 33574356
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Szokol B; Gyulavári P; Baska F; Ibolya K; Greff Z; Szántai KC; Zoltán O; Peták I; Axel U; Vantus T; Kéri G; Orfi L
    Acta Pharm Hung; 2013; 83(4):121-33. PubMed ID: 24575658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
    Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
    Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.